CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
11βmethyl nortestosterone dodecylcarbonate 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02754687
NCT02754687Phase 1Completed
CompareCT.gov

Single Dose, Dose-Ranging Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

Premier Research·interventional·Posted Apr 28, 2016·Updated Oct 31, 2025

In Brief

A Phase 1 clinical trial evaluating Placebo and 11βmethyl nortestosterone dodecylcarbonate for Healthy Men and Male Contraception. Completed, enrolled 12 participants across 2 sites.

Detailed Summary

The long term objective is to develop a new male hormone 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) as a male hormonal contraceptive.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Men, Male Contraception
CountriesUnited States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Washington, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 28, 2016
Enrollment StartJul 14, 2016
Primary CompletionJan 23, 2017
Study CompletionJun 5, 2017
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.2 years ago

Interventions

Placebodrug

Placebo with capsules that look like the 11β-MNTDC capsules but with no active ingredients

11βmethyl nortestosterone dodecylcarbonatedrug

Escalating doses of 100, 200, 400, and 800 mg 11β-MNTDC